Watchlist Price Alert

Charles River Laboratorie... (CRL)

NYSE: CRL · Real-Time Price · USD

118.33

1.44 (1.23%)

At close: May 02, 2025, 3:59 PM

118.46

0.11%

After-hours: May 02, 2025, 05:20 PM EDT

1.23% (1D)

Bid	113
Market Cap	5.81B
Revenue (ttm)	4.05B
Net Income (ttm)	12.58M
EPS (ttm)	0.2
PE Ratio (ttm)	591.65
Forward PE	11.38
Analyst	Hold

Ask	124.91
Volume	748,473
Avg. Volume (20D)	1,705,548
Open	120.35
Previous Close	116.89
Day's Range	118.30 - 121.72
52-Week Range	91.86 - 254.15
Beta	1.45

About CRL

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent r...

Sector Healthcare

IPO Date Jun 23, 2000

Employees 18,700

Stock Exchange NYSE

Ticker Symbol CRL

Website https://www.criver.com

Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for CRL stock is "Hold." The 12-month stock price forecast is $174, which is an increase of 47.05% from the latest price.

Stock Forecasts

Next Earnings Release

Charles River Laboratories International Inc. is scheduled to release its earnings on May 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

-28.13%

Charles River Laboratories shares are trading high... Unlock content with Pro Subscription

3 months ago

-6.34%

Charles River Laboratories shares are trading lower after the company announced a year-over-year decrease in preliminary FY25 revenue.

News

4 days ago · zacks.com

Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 days ago · businesswire.com

Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--The Charles River Incubator Program announces its first cohort, expediting the development of technologies and life-changing therapies for patie...

5 days ago · zacks.com

Here's How Charles River is Placed Just Ahead of Q1 Earnings

CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.

1 week ago · businesswire.com

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology dr...

1 week ago · seekingalpha.com

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity

Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data....

2 weeks ago · marketbeat.com

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?

It's been a turbulent start to 2025 for investors. The market has faced a wave of selling pressure driven by surging tariffs, escalating geopolitical tensions, and growing fears of a global economic s...

2 weeks ago · businesswire.com

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules first-quarter 2025 earnings release and conference call.

2 weeks ago · zacks.com

Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?

Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increas...

3 weeks ago · benzinga.com

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.

3 weeks ago · zacks.com

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Load More News